Australia Extends Biosimilar Education Efforts
GBMA-Led Biosimilar Education Program Will Now Run To June 2022
Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.
You may also be interested in...
AbbVie is spreading confusion among Australian doctors and patients with anti-competitive materials designed to fend off biosimilar adalimumab competition to Humira, according to a local biosimilars industry association.
Lupin has broadened its reach in Australia after agreeing a deal to buy local generics developer and distributor Southern Cross.
US-based giant Amgen has seen its Mvasi biosimilar become the sole bevacizumab product listed on Australia’s Pharmaceutical Benefits Scheme.